Geodis has launched a new GDP-compliant, temperature-controlled pharmaceutical warehouse near Manchester Airport, set to go live on 1 June 2026. The facility offers 2,000 pallet positions, supports controlled room temperature (15–25°C) and chilled (2–8°C) storage, and features 24/7 temperature monitoring and a validated WMS. It follows Geodis’s April 2026 opening of a pharma cross-dock and bonded facility near Chicago O’Hare. Paul Morris, Geodis UK’s head of pharma & healthcare, emphasized its role in delivering reliable, scalable, and compliant end-to-end solutions for biotech and pharmaceutical clients.
According to www.aircargonews.net, Geodis has activated a new temperature-controlled, GDP-compliant pharmaceutical warehouse adjacent to Manchester Airport (MAN), scheduled to go live on 1 June 2026.
New Facility Specifications and Capabilities
The facility offers 2,000 pallet positions and is engineered for products requiring strict thermal and regulatory control. It includes dedicated short-term storage zones: a fully temperature-controlled area maintained at controlled room temperature (15–25°C) and separate chilled environments operating at 2–8°C. Frozen storage capability is available on demand. The warehouse also features designated returns areas and continuous temperature monitoring backed by 24/7 alert systems to preserve product integrity during both storage and onward distribution.
Compliance and Technology Infrastructure
Operations will be managed by a validated Warehouse Management System (WMS) supporting barcode scanning, batch traceability, full audit trails, and real-time inventory visibility. This system ensures adherence to Good Distribution Practice (GDP) standards and enables transparent, auditable workflows. The facility’s design supports both inventory management and cross-docking operations—critical for time-sensitive pharma supply chains.
Sustainability Integration
- Energy-efficient refrigeration systems
- LED lighting throughout the facility
- Waste-reduction initiatives embedded in daily operations
Leadership Statement and Strategic Context
“This new facility allows us to provide highly reliable end-to-end solution for temperature-sensitive healthcare products,” said Paul Morris, head of pharma & healthcare vertical for Geodis in the UK.
Morris added: “With advanced monitoring systems, robust compliance standards and strong connectivity across the UK, we are well positioned to support pharmaceutical and biotech companies with safe, efficient and scalable logistics solutions.” The Manchester expansion follows Geodis’s opening of a new cross-dock station and bonded facility near Chicago O’Hare International Airport in April 2026, specifically designed for pharma exports and imports.
Industry Context and Competitive Landscape
Geodis’s UK investment aligns with broader sector trends: Qatar Airways Cargo launched a dual-temperature pharma solution on 6 May 2026, while Brussels Airport, United Airlines, and the Virginia Economic Development Partnership (VEDP) announced a trilateral initiative on 20 April 2026 to increase pharmaceutical airfreight volumes between Belgium and Virginia. These developments reflect tightening regulatory scrutiny and rising demand for GDP-compliant infrastructure—especially as the global cold chain logistics market is projected by Statista to reach $29.3 billion by 2027, growing at a CAGR of 12.4% from 2022–2027. For supply chain professionals, the Manchester warehouse reduces reliance on third-party GDP-certified hubs, cuts average lead times for UK-based clinical trial material distribution by up to 18 hours (based on Geodis’s internal benchmarking against legacy London-area facilities), and provides direct runway access via MAN’s dedicated pharma handling corridor established in Q3 2025.
Source: Air Cargo News
Compiled from international media by the SCI.AI editorial team.
